1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in France, MarketLine

Generics in France, MarketLine

  • January 2016
  • -
  • MarketLine
  • -
  • 32 pages

Introduction

Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights

- For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

- The French generics market is expected to generate total revenues of $4.2bn in 2015, representing a compound annual growth rate (CAGR) of 2% between 2011 and 2015.

- Market consumption volume is forecast to reach a total of 32.8 % of total pharma volume in 2015.

- Generic sales were hit by price cuts in 2014. However, an advertising campaign will begin at the end of 2015, which aims to build confidence in generic drugs. This should see the market begin to grow again within the next few years.

Features

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France

- Leading company profiles reveal details of key generics market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts by both value and volume

- Macroeconomic indicators provide insight into general trends within the France economy

Key Questions Answered

- What was the size of the France generics market by value in 2015?

- What will be the size of the France generics market in 2020?

- What factors are affecting the strength of competition in the France generics market?

- How has the market performed over the last five years?

- How large is France’s generics market in relation to its regional counterparts?

Table Of Contents

Generics in France, MarketLine
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market volume 9
Market Segmentation 10
Geography segmentation 10
Market Outlook 11
Market value forecast 11
Market volume forecast 12
Five Forces Analysis 13
Summary 13
Buyer power 14
Supplier power 15
New entrants 16
Threat of substitutes 17
Degree of rivalry 18
Leading Companies 19
Les Laboratoires Servier 19
Sandoz International GmbH 20
Sanofi SA 21
Teva Pharmaceutical Industries Limited 24
Macroeconomic Indicators 27
Country Data 27
Methodology 29
Industry associations 30
Related MarketLine research 30
Appendix 31
About MarketLine 31

List of Tables
Table 1: France generics market value: $ billion, 2011-15(e)
Table 2: France generics market volume: % of total pharma volume, 2011-15(e)
Table 3: France generics market geography segmentation: $ billion, 2015(e)
Table 4: France generics market value forecast: $ billion, 2015-20
Table 5: France generics market volume forecast: % of total pharma volume, 2015-20
Table 6: Les Laboratoires Servier: key facts
Table 7: Sandoz International GmbH: key facts
Table 8: Sanofi SA: key facts
Table 9: Sanofi SA: key financials ($)
Table 10: Sanofi SA: key financials (€)
Table 11: Sanofi SA: key financial ratios
Table 12: Teva Pharmaceutical Industries Limited: key facts
Table 13: Teva Pharmaceutical Industries Limited: key financials ($)
Table 14: Teva Pharmaceutical Industries Limited: key financial ratios
Table 15: France size of population (million), 2011-15
Table 16: France gdp (constant 2005 prices, $ billion), 2011-15
Table 17: France gdp (current prices, $ billion), 2011-15
Table 18: France inflation, 2011-15
Table 19: France consumer price index (absolute), 2011-15
Table 20: France exchange rate, 2011-15

List of Figures
Figure 1: France generics market value: $ billion, 2011-15(e)
Figure 2: France generics market volume: % of total pharma volume, 2011-15(e)
Figure 3: France generics market geography segmentation: % share, by value, 2015(e)
Figure 4: France generics market value forecast: $ billion, 2015-20
Figure 5: France generics market volume forecast: % of total pharma volume, 2015-20
Figure 6: Forces driving competition in the generics market in France, 2015
Figure 7: Drivers of buyer power in the generics market in France, 2015
Figure 8: Drivers of supplier power in the generics market in France, 2015
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2015
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2015
Figure 11: Drivers of degree of rivalry in the generics market in France, 2015
Figure 12: Sanofi SA: revenues and profitability
Figure 13: Sanofi SA: assets and liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.